Nestle Health Science enters microbiome research venture

929c1134-8d44-4139-8110-035684bd4b33articleimage.jpg

13 Jul 2017 --- Nestlé Health Science and Enterome are establishing Microbiome Diagnostics Partners (MDP), in an attempt to lead the development and commercialization of innovative microbiome-based diagnostics with the potential to transform therapeutic approaches across health conditions such as inflammatory bowel diseases (IBD) and liver diseases. The partnership follows Nestlé Health Science’s initial investment announced in April 2016.

“Mastering the microbiome is an important facet of our strategy to advance the therapeutic role of nutrition. We also see new opportunities for personalized nutrition both for the healthy population and for patients. The two initial programs have great potential to become differentiated diagnostics,” says Greg Behar, CEO of Nestlé Health Science.

According to the companies, MDP will initially aim to boost Enterome’s diagnostic programs, which include IBD 110 for the assessment and management of mucosal healing and MET210 for NASH (non-alcoholic steatohepatitis). The current standard of care for these conditions include invasive procedures such as endoscopy and biopsies, rather than a non-invasive stool/serum combined Dx tests that will be developed by MDP. Future innovation efforts will leverage advanced microbial and serum-based metabolic technologies developed respectively at Enterome and Nestlé Health Science’s diagnostics arm Prometheus Laboratories.

The companies announced that Microbiome Diagnostics Partners is to be a 50:50 joint venture between Enterome and Nestlé Health Science. Prometheus (a Nestlé Health Science Company) will contribute its Diagnostics (Dx) development and commercialization expertise. Enterome will contribute its current microbiome diagnostic programs and intellectual property (IP) derived from its unique microbiome-based platform for the development of Dx in all therapeutic areas except immuno-oncology. 

Nestlé Health Science will reportedly invest €20 million in return for its 50 percent stake in MDP and exclusive commercialization options on the initial programs. In addition to this investment, MDP will receive further milestone payments linked to the success of clinical and commercial activities.

Commenting on the move, Behar says, “Microbiome Diagnostics Partners is equipped to lead diagnostic discovery in the microbiome field, opening the door to innovative therapeutic approaches combining diagnostics (Dx), nutritional therapies (Nx) and therapeutics (Rx).” 

“The formation of Microbiome Diagnostics Partners is an important milestone for Enterome, as it brings together powerful and complementary technologies and capabilities to enable the creation of a new generation of diagnostic and companion diagnostic products. The MDP joint venture will leverage Enterome’s microbiome-based platforms in diagnostic areas, while Enterome will continue to focus on their application for the discovery of novel small molecule therapeutics,” comments Pierre Belichard, CEO of Enterome.

To contact our editorial team please email us at editorial@cnsmedia.com

Related Articles

Nutrition & Health News

Probiotic peanut allergy treatment: Chr. Hansen enters new partnership

18 Apr 2018 --- Probiotic strain, LGG, can potentially play a part in peanut allergy treatment. Prota Therapeutics, developer of oral immunotherapies to treat food allergies, has partnered with Chr. Hansen, Danish food ingredients producer, to assess LGG in a clinical trial to develop a treatment for the allergy. Chr. Hansen tells NutritionInsight that the partnership is in effect as from today, and strengthens the position of Chr. Hansen in a market expected to grow to €10billion by 2025.

Nutrition & Health News

Time to get personal? How to embrace digital technology in tomorrow’s nutraceuticals

12 Apr 2018 --- Within the world of nutrition, personalization has quickly climbed the ranks to become a key industry phrase, with both larger players and newer start-ups seeking to profile themselves as capable of offering their customers, and ultimately consumers, cutting-edge solutions for all their health needs. NutritionInsight looks at some of the developments in this space, as well as the challenges involved in the pivotal strategy of using digital tools with personal consumer input.

Nutrition & Health News

DSM: Stress-free beauty with a millennial focus

11 Apr 2018 --- DSM, one of the industry’s leading suppliers of ingredients and solutions to the personal care and aroma markets, will be showcasing ideas for easing consumer stress and detailing its strategy for meeting the societal challenges of skin cancer at this year’s “in-cosmetics” global trade show, in Amsterdam.

Packaging & Technology News

Zinc in canned goods can restrict nutrient absorption, study finds

10 Apr 2018 --- Zinc nanoparticles that are present in tinned foods may negatively affect how the digestive tract operates, as they are absorbed into the bloodstream, a study has found. Researchers at Binghamton University, State University at New York, found that the nanoparticles may decrease nutrient absorption in digestion, as well as bump up the levels of zinc in the food itself to 100 times the daily allowance. The long-term effect on human health is unknown and is something that warrants future research, the researchers state.

Nutrition & Health News

Gut-brain axis: NZMP SureStart joins research program to aid infant formula development

09 Apr 2018 --- NZMP SureStart, the global B2B pediatric ingredients brand of Fonterra, has joined Smarter Lives, a five-year research program that investigates how nutrition impacts the gut-brain axis. Smarter Lives is funded by New Zealand’s Ministry of Business, Innovation and Employment and led by New Zealand research institute, AgResearch. It will investigate how foods influence brain function via the sophisticated communication systems between the gut and the brain.

More Articles
URL : http://www.nutritioninsight.com:80/news/nestle-health-science-enters-microbiome-research-venture.html